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Abstract. Purpose: The folate receptor (FR) is a valuable
tumour marker, since it is frequently overexpressed on
various cancer types. The purpose of the present study was
to pre-clinically evaluate novel site-specifically modified
99mTc(CO)3 folate (γ-derivative 4, α-derivative 5) and
pteroate (6) conjugates for FR targeting.
Methods: The 99mTc(CO)3 radiotracers 4–6 were prepared
by a kit-like procedure. In vitro characterisation (KD and
Bmax) of the radiotracers was performed with FR-positive
KB cells. Tissue distribution was studied in tumour-
bearing mice. SPECT/CT experiments were performed
with a dedicated small animal SPECT/CT scanner.
Results: The complexes 4–6 were formed in high yields
(>92%). Binding constants of the radiotracers (KD in nM:
4: 2.09; 5: 2.51; 6: 14.52) were similar to those of 3H-folic
acid (KD in nM: 7.22). In vivo the folate derivatives
showed significantly better tumour uptake (4: 2.3±0.4%
ID/g and 5: 1.2±0.2% ID/g, 4 h p.i.) than the pteroate
derivative (6: 0.4±0.2% ID/g, 4 h p.i.). Clearance of all
radiotracers from the blood pool and from non-targeted
tissues was efficient (tumour to blood ratio approx. 200–
350, 24 h p.i.). FR-positive tissue and organs were
successfully visualised via small animal SPECT/CT.
Conclusion: Radiotracers 4–6 are the first 99mTc(CO)3
tracers prepared via a kit formulation which exhibit full
biological activity in vitro and in vivo. Folate derivatives 4
and 5 revealed significantly better pharmacokinetic
properties than the pteroate derivative 6. Promising pre-
clinical SPECT results warrant further assessment of 99mTc
(CO)3 radiofolates for detection of FR-positive tumours.
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Introduction
The folate receptor (FR) is a high-affinity, membrane-
anchored protein which mediates the transport of folic acid
and its conjugates into the cell interior by endocytosis.
Excessive need of rapidly dividing malignant cells for
folates may be a reason for the frequent overexpression of
FRs in various cancer types (e.g. ovarian, endometrial,
breast, nasopharyngeal, renal and colorectal cancers) [1–5].
Therefore, folic acid has been identified as the prototype of
a “Trojan horse” approach to specific tumour targeting for
diagnostic and therapeutic purposes [6, 7]. To date, a
number of folate conjugates (e.g. of chemotherapeutic
agents [8], antisense oligonucleotides [9], protein toxins
[10] and liposomes [11]) have successfully been prepared
and evaluated in vitro and in vivo. Various groups are
currently developing folate-based radiopharmaceuticals,
labelled with diverse diagnostic radionuclides (e.g.
66/67/68Ga, 111In, 99mTc) [12–21].
The development of radiopharmaceuticals for labelling
with the “matched pair” 99mTc/188Re (99mTc: 6-h half-life,
140-keV γ-radiation; 188Re: 17-h half-life, 2.12-MeV
β-max-radiation) remains an attractive goal because of the
excellent decay of these radionuclides, their low cost and
their excellent, carrier-free availability. Moreover, techne-
tium and rhenium share many chemical similarities which
potentially enable application of structurally almost
identical compounds for either diagnosis or therapy. The
group of Leamon and co-workers has recently reported the
pre-clinical development of a 99mTc-radiolabelled folate
derivative, 99mTc-EC20 [20, 21]. Their labelling strategies
successfully employed a tetradentate N/S-containing bi-
functional chelating system for complexation of the 99mTc
(+V)-oxo core.
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Our ongoing research programmes are focussing on the
development of organometallic 99mTc(I)- and 188/186Re(I)-
radiolabelled tumour-targeting agents, because Re(I) com-
plexes have proven to be kinetically more inert than Re(V)
complexes [22, 23]. Because of the high stability (kinetic
inertness) and favourable labelling characteristics, the
99mTc/188Re-tricarbonyl approach represents an attractive
radiolabelling strategy for the preparation of folate deriv-
atives featuring target-specific activity for diagnosis and
therapy [24–28].
Recently, we reported the synthesis of γ-folate (1), α-
folate (2) and pteroate (3) derivatives, functionalised with
the picolylamine monoacetic acid (PAMA)-chelating
system for labelling with [M(CO)3(OH2)3]
+ (M=99mTc,
natRe) [29]. In the study presented here, we wished to report
on the development of a new and convenient kit prepara-
tion of folate and pteroate analogues starting directly from
[Na][99mTcO4]. In addition, we report the first in vitro and
in vivo studies of these three novel, organometallic 99mTc-
folate/pteroate radiotracers in the FR-overexpressing KB
cancer cell line and tumour xenografts thereof. Differences
between folate and pteroate derivatives with regard to FR-
binding properties and pharmacokinetics were analysed. In
vivo SPECT/CT studies with the most promising candidate
were performed in anaesthetised mice bearing FR-positive
KB cell xenografts. These studies clearly unveiled the high
potential of this new 99mTc-based radiofolate for specific
visualisation of FR-positive tumour tissue.
Materials and methods
General
PAMA-γ-folate, PAMA-α-folate and PAMA-pteroate conjugates were
synthesised as previously reported [29]. [3′,5′,7,9-3H]Folic acid
potassium salt (37 MBq/ml, 888 GBq/mmol) was purchased from
Amersham Biosciences (Buckinghamshire, UK). The scintillation
solution Ultima Gold, high flash-point LSC-cocktail was purchased
from Packard Company (Groningen, the Netherlands). Precursor
[99mTc(OH2)3(CO)3]
+was prepared using the Isolink kit (Mallinckrodt-
Tyco, Petten, the Netherlands). [Na][99mTcO4] was eluted from a
99Mo/99mTc generator (Mallinckrodt-Tyco, Petten, the Netherlands)
with a 0.9% saline solution. KB cells (CCL-17) were purchased from
ATCC (American Type Culture Collection, Manassas, USA). Special
RPMI cell culture medium (without folic acid, vitamin B12, phenol red)
was purchased from Cell Culture Technologies GmbH (Gravesano/
Lugano, Switzerland). HPLC analyses were performed on a
Merck-Hitachi L-6200A-system equipped with an L-3000 tunable
absorption detector, a Berthold LB 508 radiometric detector and an
XTerra (Waters) MS C-18 reversed phase column (5 μm,
15 cm×4.6 mm). HPLC solvents: aqueous 0.05 M triethylammonium
phosphate buffer, pH 7.0 (solvent A), methanol (solvent B). The HPLC
system started with 100%Awith a linear gradient to 20%A and 80%B
over 15min, followed by 5min of 100%Awith a flow rate of 1ml/min.
Radioactivity (γ-radiation of 99mTc) was measured with a γ-counter
(Cobra II, Model B 5003, Packard) and (β-radiation of 3H) with a
β-counter (TRI-CARB, 1900 TR, Liquid Scintillation Analyzer,
Packard). Protein concentrations for the in vitro experiments were
measured with a microplate reader (Bio-Rad, Model 550), using a
Micro BCA Protein Assay kit (Prod # 23235), Socochim. A combined
small-animal SPECT/CT device (X-SPECT, Gamma Medica Inc.,
Northridge, CA, USA) with a single-head SPECT camera and CT
detector was used for in vivo imaging.
Cell cultures
KB cells (human nasopharyngeal carcinoma cell line) were cultured
continuously in 150-cm2 flask as monolayers at 37°C in a humidified
atmosphere containing 7.5% CO2. The cells were propagated in
folate-deficient special RPMI 1640 medium (FFRPMI: modified
RPMI 1640 medium without folic acid, vitamin B12 and phenol red),
supplemented with 10% heat-inactivated fetal calf serum (FCS, as
the only source of folate), L-glutamine and antibiotics (penicillin 100
IU/ml, streptomycin 100 μg/ml, fungizone 0.25 μg/ml). Cell culture
media such as FCS-supplemented FFRPMI are known to feature a
final folate concentration of ∼3 nM, i.e. a value at the low end of the
physiological concentration in human serum [30]. Cell preparation
for in vitro experiments was as follows: 18–20 h prior to each
experiment, the cells were seeded in 12-well plates (∼8×105 cells/
well) and incubated at 37°C to form confluent monolayers overnight.
Experiments were performed in triplicate for each point in time and/
or concentration. Cell preparation for in vivo experiments was as
follows: For subcutaneous inoculation of the mice, subconfluent cells
were harvested by treatment with EDTA (1 mM) in phosphate-
buffered saline (PBS, 1×, pH 7.4). The cells were then washed once
with PBS and pelleted by spinning at 1,000×g for 5 min at 20°C. The
cells were resuspended in PBS to a final concentration of
50×106 cells/ml.
Preparation of the radiotracers 4–6
99mTc(CO)3-PAMA-γ-folate (4),
99mTc(CO)3-PAMA-α-folate (5)
and 99mTc(CO)3-PAMA-pteroate (6) radiotracers were prepared
according to the following general procedures: In method I a neutral
solution of fac-[99mTc(OH2)3(CO)3]
+(100 μl), PBS (pH 7.4, 350 μl)
and a stock solution of the corresponding derivative (1–3, 50 μl,
10−3M in PBS) were mixed in a sealed glass vial. The reactions were
heated for 30 min at 75°C to form the corresponding complexes 4–6
in excellent yields (>95%). In method II the derivatives 1–3
(0.1 μmol) and the components of the Isolink kit (4.5 mg Na2[H3-
BCO2], 2.9 mg B4Na2O7, 7.8 mg Na2CO3, 9.0 mg NaKC4H4O64-
H2O) were placed in a sealed glass vial. 1 ml [Na][
99mTcO4] was
added. After 45-min reaction time at 100°C, the vial was cooled on
ice and neutralised with 0.2 ml of a 1:2 mixture of 1 M phosphate
buffer (pH 7.4) and 1 M HCl. 99mTc(CO)3 complexes 4–6 were
formed at a yield of >92%. The radiolabelled complexes 4–6 were
separated from unlabelled compounds 1–3 by high-performance
liquid chromatography (HPLC). Due to HPLC purification, the
specific activities of radiotracers 4–6 can be considered identical with
that of 99mTc in the generator eluate, 26 h post elution (approx.
5.02 TBq/μmol). The solutions were further diluted to a final
concentration of 1 MBq/ml for in vitro experiments or 3.7 MBq/ml
for in vivo experiments. For SPECT experiments with complex 4,
solutions were prepared with a radioactivity of 3 GBq/ml.
Time-dependent cell uptake
Cell binding experiments with radiotracers 4–6 were performed
according to the following general procedure: cell monolayers were
rinsed twice with ice-cold PBS (pH 7.4). Pure FFRPMI medium
(without FCS/L-glutamine/antibiotics, 975 μl) was added to each
well. The well plates were pre-incubated at 37°C for 10 min. A
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solution of the respective radiotracer 4–6 (25 μl, 1 MBq/ml) was
added and the well plates were incubated again at 37°C for 5, 15, 30,
60, 120 and 240 min. After the corresponding incubation period the
monolayers were washed several times. Counted radioactivity in
samples, washed with PBS (pH 7.4) only, could be ascribed to the
sum of FR-bound radiotracer on the cell surface and the internalised
fraction. Cell samples, washed with stripping buffer (aqueous
solution of 0.1 M acetic acid and 0.15 M NaCl, pH 3) in order to
release radiotracer from FRs on the cell surface, enabled the
determination of the internalised fraction of radioactivity [31, 32]. In
this way, it was possible to distinguish between total bound
radiotracer and the internalised fraction. The cell monolayers were
lysed in 1 N NaOH (1 ml), transferred to 4-ml tubes and
homogenised by vortex. Each sample was counted for radioactivity
with a γ-counter, using reference counts from samples which
contained the total amount of originally added radioactivity. The
concentration of proteins was determined for each sample using a
Micro BCA Protein Assay kit in order to normalise measured
radioactivity in each sample with respect to the averaged sample
protein content. The raw data of measured radioactivity corresponded
to the sum of bound and internalised radioactivity or internalised
radioactivity only. The data were converted from counts per minute
(cpm) per mg protein into percentage of total added radioactivity.
Determination of KD and Bmax of compounds 4–6 and
3H-folic acid
The experiments were performed at 4°C in order to attenuate
endocytosis. Since addition of excess folic acid resulted in <0.5%
residual radioactivity (data not shown), non-specific binding of the
radiotracers could be neglected. Inhibition experiments with the
folate and pteroate radiotracers 4–6 and 3H-folic acid were performed
according to the following procedure: The monolayers were rinsed
twice with ice-cold PBS (pH 7.4). Pure ice-cold FFRPMI medium
(without FCS/L-glutamine/antibiotics, 475 μl) was added to each
well. Then, 500 μl of the corresponding ice-cold folic acid solution
(ten different concentrations from 0.001 μM to 0.2 μM, prepared in
PBS, pH 7.4) was added. The well plates were pre-incubated at 4°C
for 40 min. A solution of the corresponding radiotracer 4–6 (25 μl,
1 MBq/ml) or 3H-folic acid (25 μl, ∼19 kBq) was added and the well
plates were incubated again at 4°C for 2 h. The monolayers were
washed three times with PBS (pH 7.4). The cell monolayers were
lysed in 1 N NaOH (1 ml), transferred to 4-ml tubes and
homogenised by vortex. The concentration of proteins was
determined for each sample by a Micro BCA Protein Assay kit.
Samples of radiotracers 4–6 were counted for radioactivity with a γ-
counter and samples of 3H-folic acid were, after mixing with a
scintillation solution, counted in a β-counter. KD and Bmax values
were determined by converting the raw data of measured radioac-
tivity from cpm bound per mg protein into pmol radiotracer bound
per mg protein and analysed by Rosenthal plot. The mean values for
KD and Bmax of each radiotracer (4–6) and
3H-folic acid, acquired in
two independent experiments, are shown in Table 1. The values
shown in parentheses represent the lower and upper limits of the 95%
confidence interval.
Dissociation and externalisation experiment
Dissociation and externalisation studies of the radiotracer 4 were
performed according to the following procedure: The monolayers
were rinsed twice with ice-cold PBS (pH 7.4). Pure FFRPMI medium
(without FCS/L-glutamine/antibiotics, 975 μl) was added to each
well and the well plates pre-incubated at 37°C for 10 min. A solution
of the radiotracer 4 (25 μl, 1 MBq/ml) was added to each well and the
well plates incubated for 2 h at 37°C. The cell monolayers were then
washed with either PBS or stripping buffer (t=0) [31, 32]. Pure
FFRPMI medium (without FCS/L-glutamine/antibiotics, 1 ml) was
added to each well and the well plates were incubated again for 2 h at
37°C (t=2 h). After washing the cells as described above, fresh
FFRPMI medium (without FCS/L-glutamine/antibiotics, 1 ml) was
again added to each well. The cells were incubated for another 3 h
(t=5 h). This procedure was repeated after an incubation period of
12 h (t=17 h). Each of the supernatants, combined with the
corresponding wash solutions, was transferred to a 4-ml tube and
counted for radioactivity. Counts measured in each sample were
analysed and expressed as percentage of the sum of total cell-bound
and internalised radioactivity at t=0 (100%).
In vivo studies
Four- to 5-week-old female, athymic nude mice (CD1-Foxn1/nu)
were purchased from Charles River Laboratories (Sulzfeld, Ger-
many). Mice were housed under conditions of controlled temperature
(26°C), humidity (68%) and daily light cycle (12 h light/12 h dark).
The animals were fed with a folate-deficient rodent chow in order to
reduce their serum folate to a level near that of human serum [13].
After an acclimation period of 5–7 days, the mice were inoculated
subcutaneously with 0.1 ml tumour cell suspension (50×106 cells/ml)
into the subcutis of the axilla. Radiotracer distribution studies were
performed 12–14 days after tumour cell inoculation. Radiotracers 4–6
(approx. 370 kBq per mouse) were administered via a lateral tail vein.
To competitively block tissue FRs, mice were injected with excess
folic acid (0.25 μmol in PBS pH 7.4) 5 min prior to administration of
the radiotracer. At the indicated points in time the animals were
sacrificed and dissected. The selected tissues were removed and
weighted, and the radioactivity was counted by a γ-counter to
determine tissue distribution of the radiotracers within the test animal.
In vivo biodistribution studies were performed in triplicate for each
radiotracer (4–6) and time point. The results were tabulated as
percentage of the injected dose per gram of tissue (% ID/g), using
reference counts from a definite sample of the original injectate.
Table 1. Binding constants of radiotracers 4–6 and 3 H-folic acid in KB cells, determined by Rosenthal analysis
Radiotracer Bmax (pmol/mg protein) KD (nM)
99mTc(CO)3-PAMA-γ-folate (4) 14.7 (−22.1 to +51.5) 2.09 (−11.5 to +15.7)
99mTc(CO)3-PAMA-α-folate (5) 6.0 (+3.4 to +8.7) 2.51 (−6.2 to +11.2)
99mTc(CO)3-PAMA-pteroate (6) 7.7 (−1.5 to +16.9) 14.52 (−16.7 to +45.8)
3H-folic acid 11.9 (−12.2 to +36.0) 7.22 (−11.2 to +25.6)
Values shown in parentheses represent the lower and upper limits of the 95% confidence interval; number of experiments =2
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SPECT imaging studies
Imaging experiments were performed 24 h p.i. of radiotracer 4. The
radiotracer (approx. 550 MBq) was administered via a lateral tail
vein. The mice were anaesthetised with an isoflurane/oxygen
mixture. Depth of anaesthesia was monitored by measuring respi-
ratory frequency using a respiratory belt. Body temperature was
controlled by a rectal probe and kept at 37°C by a thermocoupler and
a heated air stream. SPECT data were acquired and reconstructed by
software LumaGEM (version 5.407 lum 10). CT data were acquired
by the manufacturer’s software and reconstructed with the software
COBRA (version 4.5.1). Fusion of SPECT and CT data was
performed by software IDL Virtual Machine (version 6.0). Images
were generated by software Amira (version 3.1.1).
Results
Synthesis of the radiotracers
Radiolabelling of ligands 1–3 was performed either by
the two-step (method I) or a new, one-step, kit-like
procedure (method II, Fig. 1). For method I, the
precursor [99mTc(CO)3(OH2)3]
+ was prepared first by
the Isolink kit, followed by neutralisation with phos-
phate/HCl buffer. Then, the precursor was added to a
solution of the corresponding derivatives 1–3 in PBS.
After heating at 75°C for 30 min, the complexes 4–6
were formed almost quantitatively (>95% yield) [29].
For method II, the folate precursors 1–3 (0.1 μmol) were
placed together with the Isolink components in a 10-ml
vial, sealed and flushed with nitrogen. After addition of
1 ml of [99mTcO4]
− the reactions were heated for 45 min
at 100°C followed by neutralisation (Fig. 1). The
formation of radiotracers 4–6 was observed in excellent
yields (>92%), comparable to the data obtained by the
two-step reaction. The amount of (unidentified) byprod-
ucts ranged between 2% and 8% of the total radioactivity
for both methods. Also the HPLC traces of the non-
radioactive precursors 1–3 (observed at λ=254 nm),
analysed after the labelling reaction, revealed only minor
formation of non-radioactive byproducts (Fig. 2). This
proved the high stability of the folate precursors even
under reductive and basic reaction conditions and hence
their suitability for an Isolink adapted kit formulation.
Tridentate coordination of the [99mTc(CO)3]
+ core to
ligands 1–3 resulted in a significant shift in the HPLC
retention times (4, 5: Rt=15.5 min and 6: Rt=16.5 min)
compared with those of the free ligands 1–3 (1, 2:
Rt=11.5 min and 3: Rt=12.5 min) (Fig. 2). This enabled
the clear separation and purification of radiotracers 4–6
from non-radioactive precursors 1–3 in order to achieve
high specific activities necessary for in vitro and in vivo
studies. High stability of radiotracers 4–6 in PBS as well
as in human plasma has been previously tested and
proven [29].
In vitro studies
Binding and internalisation studies were performed at 37°C
over a period of 4 h (Fig. 3). The sum of FR-bound radio-
tracers 4–6 and the internalised fractions was calculated as
percentage of total added radioactivity, determined by
residual cell-associated radioactivity after washing the
monolayers with PBS (pH 7.4) [33]. The internalised
fractions of the radiotracers 4–6 were ascribed to the radio-
activity, measured after washing the cells with stripping
buffer (pH 3). No significant differences could be observed
between the folate radiotracers 4 and 5 and the pteroate
derivative 6. After 4-h incubation at 37°C, 40–60% of total
radioactivity was bound, of which 25–35% was inter-
nalised. The results obtained for the folate conjugates 4 and
5 and the pteroate conjugate 6 were within the same range.
Blocking experiments were carried out with cells which
were pre-incubated with excess folic acid (100 μM) for
Fig. 1. Structure and preparation
of novel organometallic 99mTc
radiofolate and pteroate deriva-
tives via a two-step and a
one-step, kit formulation: i)
20 min, 100°C, neutralisation;
ii) 30 min, 75°C; iii)
Na2[H3BCO2], B4Na2O7,
Na2CO3, NaKC4H4O6, 45 min,
100°C, neutralisation
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40 min before addition of radiotracers 4–6. Under these
conditions less than 0.5% of total added radioactivity was
bound to the cells (data not shown). These experiments
proved the high specificity of the derivatives 4–6 for the
targeted FRs in vitro and negligible non-specific binding of
the radiofolates.
KD and Bmax values of the radiotracers 4–6 and
3H-folic
acid were determined by incubation of the radiotracers and
cold folic acid with KB cells for 2 h at 4°C. Since non-
specific cell binding was negligible and because endocy-
tosis was inhibited at 4°C, radioactivity detected in the
samples could be ascribed to specific cell surface-bound
radiotracer. KD values and Bmax values of the folate 4 and 5
and pteroate 6 derivatives and the parent ligand 3H-folic
acid are summarised in Table 1.KD values were observed in
the low nM range, comparable to that of 3H-folic acid. Bmax
values of compounds 4–6 ranged between 6.0 and 14.7
pmol/mg protein (95% confidence interval −22.1 to +51.5)
and were similar to that found for the parent ligand 3H-folic
acid (11.9 pmol/mg protein, 95% confidence interval −12.2
to +36.0).
Representative for all three organometallic radiotracers
4–6, dissociation of compound 4 from FRs on the cell
surface and externalisation were investigated. Radiotracer
4 was incubated with KB cells for 2 h at 37°C, followed by
washing steps with PBS for determination of total bound
and internalised radioactivity, or with stripping buffer in
order to define the acid-resistant (internalised) fraction (see
Materials and methods). Overall dissociation and exter-
nalisation of radioactivity was less than 10% after 17 h.
In vivo studies
Radiotracers 4–6 were tested for their ability to bind to FR-
positive tumour tissue in vivo. Athymic nude mice, bearing
KB cell tumour xenografts, were used for biodistribution
studies performed 1 h, 4 h and 24 h post injection of the
radiotracers (Tables 2, 3 and 4). Compounds 4–6 accumu-
lated in FR-positive tissues, namely the tumours and the
kidneys. The tumour uptake 4 h p.i. was highest for the γ-
derivative 4 (2.33±0.36% ID/g), significantly lower for the
α-derivative 5 (1.24±0.19% ID/g, p<0.018) and even more
reduced for the pteroate derivative 6 (0.43±0.17% ID/g,
p<0.005). Clearance from the bloodstream was fast,
resulting in marginal amounts of radioactivity as early as
1 h post injection of the radiotracers (4: 0.09±0.02% ID/g;
5: 0.08±0.04% ID/g; 6: 0.06±0.01% ID/g) without signif-
icant differences amongst the compounds (p>0.05). Radio-
activity found in organs such as heart, lung, spleen, muscle
and bone was negligible as well. Twenty-four hours after
injection of the radiotracers, tumour-to-blood ratios reached
values between 200 and 350 for all compounds (4-6:
p>0.05). Apart from in the tumours, a significant amount of
radioactivity was found only in the kidneys (4: 18.5±0.7%
ID/g; 5: 12.4±1.9% ID/g; 6: 3.3±0.4% ID/g, 4 h p.i.). It is
noteworthy that again (i.e. as observed in tumours) the
pteroate derivative 6 showed lower uptake in kidneys than
did the folate derivatives. While absolute tumour and
kidney uptake differed among the radiotracers 4–6
(p<0.05), tumour-to-kidney ratios were similar (p>0.05)
over time for all complexes (4: 0.13±0.02; 5: 0.10±0.00; 6:
0.13±0.05; 4 h p.i.). Co-administration of folic acid
(0.25 μmol) 5 min prior to radiotracer injection resulted
in an almost complete blockade of FRs in the tumour and
Fig. 2. Representative γ-HPLC traces of complex 4 prepared with
[99mTc(CO)3(OH2)3]
+ in two steps (method I) and prepared in a
single step using [99mTcO4]
- directly (method II); UV-HPLC trace of
unlabelled folate precursor 1
Fig. 3. Time-dependent binding (■ 4, ▲ 5, ● 6) and internalisation
(☐ 4, ∆ 5, ◯ 6) of the radiotracers 4–6 to FRs of KB cancer cells,
incubated at 37°C
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the kidneys, giving rise to very low accumulation of
radioactivity (tumour: <0.05% ID/g; kidneys: <0.4% ID/g,
4 h p.i.). Biodistribution of the complexes 4–6 in other
organs and tissue were not or only marginally affected
under blockade conditions, proving the specificity of folate-
based radiotracers.
SPECT/CT studies were performed in order to visualise
the distribution of the radiotracer in a living animal. For
that reason, mice were injected with approximately 550
MBq of complex 4 and scanned 24 h later. This time point
was determined as the most favourable for imaging
purposes since the main abundance of radioactivity had
been cleared from non-targeted tissues. For the present
experiment, the animal was scanned for 30 min using a
low-resolution/high-sensitivity parallel collimator. Accu-
mulation of radioactivity was unambiguously detected in
tumours and kidneys as well as in the gastrointestinal tract
(Fig. 4a,b). The same animal was used for studies under
FR-blocked conditions (0.25 μmol folic acid, administered
5 min prior to the radiotracer). These experiments allowed
detection of radioactivity neither in the tumour tissue nor in
the kidneys, but only non-specifically distributed in the
gastrointestinal tract (Fig. 4c,d). It is important to recognise
that application of significantly higher amounts of radio-
activity/radiotracer compared with ex vivo biodistribution
studies (by a factor of ∼1,000) had no influence on FR-
mediated and non-specific tracer uptake in mice. Post-
mortem results regarding tissue distribution of radioactivity
(% ID/g) in animals injected with the amount of radiotracer
4 used for SPECT scans were in agreement with those
found in the previous time-dependent biodistribution
studies, as shown in Table 2.
Discussion
We have previously shown that folate and pteroate
derivatives can be efficiently radiolabelled with the organ-
ometallic precursor [99mTc(CO)3(OH2)3]
+when functiona-
lised with the tridentate PAMA-chelating system [29]. In
the present study, to address the potential routine applica-
tion of the new radiofolates/pteroates in a clinical setting,
we investigated the feasibility of a one-step preparation of
the corresponding compounds based on the Isolink kit. Of
particular concern was the question of whether the ligands
and their functional groups would be resistant to the harsh,
reductive labelling conditions necessary to convert
Tc(+VII) to Tc(+I). The results of our experiments
demonstrated that both folate and pteroate derivatives 1–
3 (and their functional groups) are sufficiently resistant to
the reductive component (Na2[H3BCO2]) of the Isolink kit.
Hence, we could prove that the radiolabelling and the
formation of the desired radiotracers can be efficiently
achieved at low concentrations of the organic folate/
pteroate precursors, giving rise to high specific activity
starting directly from [99mTcO4]
−. No traces of free metal
precursor or [99mTcO4]
− were detectable after the reactions.
The yields found for the kit preparation were only
marginally reduced compared with those obtained by the
classical two-step radiolabelling procedure. The amounts
of folate/pteroate derivative (approx. 0.1 μmol) used for the
labelling with the 99mTc-tricarbonyl core were comparable
to those reported by Leamon and co-workers for the
preparation of 99mTc-EC20 (0.13 μmol) [20, 21].
Binding constants (KD, Bmax) of the radiotracers 4–6
revealed retention of FR affinity in vitro compared with 3H-
folic acid, regardless of the position of derivatisation (γ- vs
α-carboxylate group) and absence of the glutamate moiety,
when tested in KB cells. A slightly increased KD value of
the pteroate derivative 6, compared with the folate
derivatives 4 and 5, might indicate a tendency for pteroate
derivatives to show decreased FR affinity. However, these
differences are marginal and not significant. Our findings
are in agreement with those reported by Leamon et al., who
performed similar studies with α- and γ-folate conjugates
of non-radioactive macromolecules [34]. They found that
Table 2. Time-dependent bio-
distribution of 99mTc(CO)3-
PAMA-γ-folate (4) using KB
tumour xenografts in athymic
nude mice
Values (% ID/g) represent the
mean±SD of data from three
animals per cohort
99mTc(CO)3-PAMA-γ-folate (4) Folic acid (0.25 μmol)
1 h 4 h 24 h 4 h
Blood 0.09±0.02 0.04±0.00 0.01±0.02 0.01±0.00
Heart 0.85±0.27 0.32±0.07 0.02±0.00 0.00±0.00
Lung 0.57±0.19 0.33±0.02 0.03±0.02 0.02±0.02
Spleen 0.20±0.03 0.15±0.04 0.01±0.02 0.01±0.01
Kidney 14.37±1.35 18.48±0.72 6.90±0.72 0.06±0.01
Stomach 0.31±0.06 0.63±0.33 3.70±6.37 3.80±5.46
Intestines 1.89±0.37 1.49±0.23 0.76±1.15 0.40±0.45
Contents of intestines 9.31±5.94 38.51±55.88 7.08±11.52 5.54±3.38
Liver 0.89±0.31 2.37±2.85 0.10±0.02 0.12±0.02
Muscle 1.06±0.33 0.54±0.05 0.05±0.04 0.04±0.01
Bone 0.76±0.22 0.31±0.07 0.03±0.04 0.01±0.01
Tumour 1.30±0.61 2.33±0.36 1.32±0.17 0.00±0.01
Tumour-to-blood ratio 15.82±11.29 58.0±12.2 255.4±115.4
Tumour-to-liver ratio 1.60±0.81 2.53±2.13 13.77±1.90
Tumour-to-kidney ratio 0.09±0.05 0.13±0.02 0.19±0.04
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γ-glutamyl- and α-glutamyl-linked derivatives were able
to bind to FR-positive cells at virtually identical levels.
Also, a pteroate derivative revealed comparable properties.
Based on our and other groups’ results, one can conclude
that selective isomeric conjugation (via the γ- or the α-
carboxylate group) is not required, and that the presence of
glutamic acid is not essential for FR binding. On the other
hand, our results suggest that absence of the glutamic acid
moiety has a significant influence on the in vivo biodis-
tribution of our organometallic pteroate tracer 6 (vide
infra).
The amount of in vitro cell binding was similar for
derivatives 4–6 over the investigated period of 4 h. The
fraction of FR-specifically associated radiotracer continu-
ously increased until reaching a steady state after approx.
2 h (Fig. 3). Washing the cells with stripping buffer (pH 3)
enabled release of FR-bound radiotracer on the cell surface
[5, 31, 32, 35]. Interestingly, the acid-resistant fraction
ascribed to internalised radiotracers of about 30% remained
almost constant over the whole period of 4 h. This indicates
that most of the FRs (about 70%) remained permanently
cell surface exposed and were not internalising when
targeted with the radiotracers. These findings are in
agreement with those of Paulos et al., who recently
reported for several cell lines that only approximately 25%
of the total cell-associated radioactivity had been inter-
nalised after 6 h [36]. Their and our data indicate a slow
time response of radiotracer/FR endocytosis and potential
recycling of the FRs. However, these processes are not yet
completely understood and might vary among different cell
lines depending on their level of FR expression as well as
the kinetics of FR-mediated uptake of folate-based
pharmaceuticals [15, 37, 38]. The slow turnover rate of
the FRs might be an unfavourable characteristic for
Table 3. Time-dependent bio-
distribution of the 99mTc(CO)3-
PAMA-α-folate (5) using KB
tumour xenografts in athymic
nude mice
Values (% ID/g) represent the
mean±SD of data from three
animals per cohort
99mTc(CO)3-PAMA-α-folate (5) Folic acid (0.25 μmol)
1 h 4 h 24 h 4 h
Blood 0.08±0.04 0.07±0.08 0.01±0.01 0.01±0.01
Heart 0.39±0.01 0.15±0.12 0.02±0.01 0.01±0.01
Lung 0.30±0.01 0.15±0.14 0.02±0.01 0.02±0.01
Spleen 0.09±0.02 0.06±0.06 0.00±0.00 0.01±0.01
Kidney 18.18±1.80 12.36±1.86 9.74±0.96 0.25±0.26
Stomach 0.78±0.19 0.47±0.13 0.63±0.67 0.11±0.07
Intestines 23.55±30.37 0.88±0.34 0.08±0.06 0.34±0.22
Contents of intestines 197.6±186.6 5.50±4.94 1.10±0.95 4.37±3.62
Liver 7.23±2.26 0.79±0.92 0.15±0.02 0.81±0.38
Muscle 0.44±0.04 0.17±0.05 0.03±0.01 0.22±0.34
Bone 0.29±0.09 0.47±0.58 0.01±0.01 0.38±0.66
Tumour 3.56±0.53 1.24±0.19 1.87±0.27 0.03±0.02
Tumour-to-blood ratio 49.32±23.56 31.44±51.16 335.1±386.0
Tumour-to-liver ratio 0.55±0.28 1.80±1.72 12.77±2.18
Tumour-to-kidney ratio 0.20±0.01 0.10±0.00 0.19±0.04
Table 4. Time-dependent bio-
distribution of the 99mTc(CO)3-
PAMA-pteroate (6) using KB
tumour xenografts in athymic
nude mice
Values (% ID/g) represent the
mean±SD of data from three
animals per cohort
99mTc(CO)3-PAMA-pteroate (6) Folic acid (0.25 μmol)
1 h 4 h 24 h 4 h
Blood 0.06±0.01 0.10±0.02 0.00±0.00 0.04±0.00
Heart 0.06±0.01 0.07±0.02 0.02±0.01 0.02±0.00
Lung 0.13±0.07 0.16±0.02 0.02±0.01 0.06±0.02
Spleen 0.12±0.16 0.06±0.00 0.01±0.01 0.02±0.01
Kidney 6.10±1.30 3.30±0.41 2.08±0.32 0.37±0.05
Stomach 0.95±0.70 8.47±9.94 0.30±0.18 25.44±44.00
Intestines 8.43±5.65 0.65±0.31 0.06±0.05 0.17±0.07
Contents of intestines 302.1±427.1 5.79±2.99 0.48±0.57 1.22±1.21
Liver 4.19±1.85 1.32±0.27 0.47±0.20 1.62±0.14
Muscle 0.08±0.05 0.05±0.03 0.02±0.02 0.01±0.00
Bone 0.09±0.10 0.03±0.01 0.03±0.01 0.01±0.00
Tumour 0.22±0.08 0.43±0.17 1.05±0.33 0.01±0.00
Tumour-to-blood ratio 3.45±0.62 4.51±1.53 217.2±40.1
Tumour-to-liver ratio 0.06±0.05 0.33±0.10 2.33±0.34
Tumour-to-kidney ratio 0.04±0.01 0.13±0.05 0.52±0.21
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effective tumour uptake of folate-based (radio)pharmaceu-
ticals. However, the in vitro experiments clearly showed
that the radiofolate complexes, even if not internalised,
remained FR-specifically and stably bound on the cell
surface over several hours.
In vivo experiments revealed significant differences for
absolute tumour uptake between the folate derivatives 4
and 5 and the pteroate derivative 6. For complexes 4 and 5
we found maximal uptake in the tumour tissue between 1
and 4 h after administration (approx. 2–3% ID/g). Fast
clearance from the blood pool could be found with all
complexes. These observations were supported by data of
other groups, suggesting that in vivo half-lives of most
folate conjugates in circulation were <5 min, predomi-
nately because of their rapid clearance via kidneys [20, 39].
Although fast and effective renal elimination is a highly
desirable feature for radiopharmaceuticals, in the case of
folate derivatives it leads to specific and relatively high
renal accumulation of radioactivity owing to physiological
FR expression in this tissue [40–43]. We also found
relatively high amounts of radioactivity in the intestines,
which might be attributed to substantial and efficient
hepatobiliary excretion of our radiotracers. It is noteworthy
that radioactivity was found in the intestinal contents, but
not in the intestinal tissue itself or in the liver. Interestingly,
hepatobiliary clearance of other folate and pteroate radio-
tracers was reported to be negligible [20, 44–46]. On the
other hand, biodistribution data and particularly tumour-to-
background ratios of radiotracers 4 and 5 were largely
comparable to and competitive with those of other folate
radiotracers reported in the literature, such as 99mTc-
HYNIC-folate, 99mTc(CO)3-DTPA-folate and
99mTc-
DTPA-folate, but also (pre)clinically evaluated folate
radiopharmaceuticals such as 111In-DTPA-folate and
99mTc-EC20 [16, 20, 21, 33, 44, 45]. What we found,
however, was that the pteroate derivative 6 revealed a
significantly inferior tumour accumulation compared with
the folate derivatives 4 and 5. These results were somewhat
surprising since the in vitro data entailed similar binding
affinity amongst the folate and pteroate derivatives. The
implications of the glutamate moiety for the pharmacoki-
netics of our radiofolates need to be further investigated. It
is evident that the folate derivatives possess more
favourable pharmacokinetic features than the pteroate
derivative. Finally, FR specificity of all three radiotracers
4–6 was unambiguously proven by co-administration of
excess folic acid, which resulted in almost complete
inhibition of the radiotracer uptake in the FR-positive
tissue and organs.
Representatively for all three radiotracers, the γ-folate
derivative 4was further evaluated in vivo using a dedicated
small-animal, single-detector SPECT/CT device. SPECT/
CT scans were successfully conducted with an anaesthe-
tised mouse bearing KB tumour xenografts. The same
animal was successfully used for blockade experiments
employing radiotracer 4 and excess non-radioactive folic
acid. The SPECT images clearly confirmed the specificity
of radiotracer 4 for the FR. Owing to the intrinsic low
tumour uptake of all three radiotracers (<2.5% ID/g) and at
the same time a large portion of radioactivity in the
intestinal contents, it was difficult to clearly delineate
different organs and tissue at early time points after
injection (1–4 h p.i.). Significantly better data were
obtained at late time points (24 h p.i.) but this restriction
obliged us to inject relatively high doses of radioactivity
(up to 550 MBq/mouse).
Fig. 4. An athymic nude mouse
with two KB tumours on the
right and left shoulder (arrows)
was scanned 24 h after radio-
tracer injection (a,b) and 24 h
later under blockade conditions
(0.25 μmol cold folic acid in-
jected 5 min prior to the radio-
tracer) (c,d). Both SPECT/CT
scans lasted for 30 min. The
SPECT images represent a co-
ronal whole-body section
through the KB tumours and
through the kidneys (a,c) as well
as a whole-body SPECT/CT
image (b,d)
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In summary, in this study we were able to demonstrate
that a “one-pot” kit-like preparation of organometallic
99mTc radiotracers which display in vitro and in vivo
retention of receptor-binding capacity is possible. The
novel 99mTc(CO)3-folate and the
99mTc(CO)3-pteroate
radiotracers were able to specifically target FR-positive
tumours as well as other FR-positive tissues. Particularly
the folate derivatives revealed excellent target specificity
and pharmacokinetic properties in vivo. Originally, the
pteroate derivative seemed attractive from a synthetic point
of view (fewer synthetic steps), but its tumour uptake is
clearly inferior to that of the folate analogues. Significant
excretion of our tracer(s) via the hepatobiliary route could
hamper their potential for diagnostic application. However,
we believe that it is premature to draw final conclusions
about the clinical usefulness of 99mTc(CO)3-folate tracers
in general. Finally, the 99mTc(CO)3-γ-folate 4 was
successfully assessed in vivo for localisation of FR-
positive organs and tissue using one of the first combined
small animal SPECT/CT devices installed in Europe. The
promising pre-clinical results warrant further investigations
in order to assess and improve organometallic 99mTc folate
derivatives for potential use in nuclear medicine.
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